vs

Side-by-side financial comparison of Venu Holding Corp (VENU) and Vivos Therapeutics, Inc. (VVOS). Click either name above to swap in a different company.

Venu Holding Corp is the larger business by last-quarter revenue ($4.5M vs $3.8M, roughly 1.2× Vivos Therapeutics, Inc.). Vivos Therapeutics, Inc. runs the higher net margin — -180.3% vs -215.5%, a 35.2% gap on every dollar of revenue. Vivos Therapeutics, Inc. produced more free cash flow last quarter ($-5.3M vs $-52.4M).

Venu Holding Corporation ("Venu") is a publicly-traded American entertainment and hospitality company based in Colorado Springs, Colorado. Founded by JW Roth in 2017 as Notes Live, Venu designs, develops, manages and owns music venues and event spaces including amphitheaters, restaurants, and concert halls in midsize cities.

Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks.

VENU vs VVOS — Head-to-Head

Bigger by revenue
VENU
VENU
1.2× larger
VENU
$4.5M
$3.8M
VVOS
Higher net margin
VVOS
VVOS
35.2% more per $
VVOS
-180.3%
-215.5%
VENU
More free cash flow
VVOS
VVOS
$47.0M more FCF
VVOS
$-5.3M
$-52.4M
VENU

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
VENU
VENU
VVOS
VVOS
Revenue
$4.5M
$3.8M
Net Profit
$-9.8M
$-6.9M
Gross Margin
78.1%
Operating Margin
-161.6%
-166.8%
Net Margin
-215.5%
-180.3%
Revenue YoY
3.4%
Net Profit YoY
-143.8%
EPS (diluted)
$-0.77
$-0.58

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
VENU
VENU
VVOS
VVOS
Q4 25
$4.5M
$3.8M
Q3 25
$5.4M
$6.8M
Q2 25
$4.5M
$3.8M
Q1 25
$3.5M
$3.0M
Q4 24
$3.7M
Q3 24
$5.5M
$3.9M
Q2 24
$4.1M
Q1 24
$3.4M
Net Profit
VENU
VENU
VVOS
VVOS
Q4 25
$-9.8M
$-6.9M
Q3 25
$-6.4M
$-5.4M
Q2 25
$-12.3M
$-5.0M
Q1 25
$-18.1M
$-3.9M
Q4 24
$-2.8M
Q3 24
$-3.9M
$-2.6M
Q2 24
$-1.9M
Q1 24
$-3.8M
Gross Margin
VENU
VENU
VVOS
VVOS
Q4 25
78.1%
Q3 25
58.0%
Q2 25
55.2%
Q1 25
50.0%
Q4 24
56.7%
Q3 24
60.5%
Q2 24
65.4%
Q1 24
56.7%
Operating Margin
VENU
VENU
VVOS
VVOS
Q4 25
-161.6%
-166.8%
Q3 25
-185.2%
-69.8%
Q2 25
-229.7%
-127.4%
Q1 25
-529.9%
-129.9%
Q4 24
-75.9%
Q3 24
-67.4%
-68.5%
Q2 24
-47.8%
Q1 24
-110.7%
Net Margin
VENU
VENU
VVOS
VVOS
Q4 25
-215.5%
-180.3%
Q3 25
-118.1%
-79.6%
Q2 25
-274.2%
-131.2%
Q1 25
-516.2%
-128.1%
Q4 24
-76.4%
Q3 24
-72.1%
-67.8%
Q2 24
-47.6%
Q1 24
-110.1%
EPS (diluted)
VENU
VENU
VVOS
VVOS
Q4 25
$-0.77
$-0.58
Q3 25
$-0.15
$-0.49
Q2 25
$0.30
$-0.55
Q1 25
$-0.48
$-0.45
Q4 24
$0.41
Q3 24
$-0.13
$-0.40
Q2 24
$-0.60
Q1 24
$-1.63

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
VENU
VENU
VVOS
VVOS
Cash + ST InvestmentsLiquidity on hand
$2.0M
Total DebtLower is stronger
$58.9M
$2.9M
Stockholders' EquityBook value
$122.7M
$-1.5M
Total Assets
$370.6M
$25.2M
Debt / EquityLower = less leverage
0.48×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
VENU
VENU
VVOS
VVOS
Q4 25
$2.0M
Q3 25
$3.1M
Q2 25
$4.4M
Q1 25
$2.3M
Q4 24
$6.3M
Q3 24
$6.3M
Q2 24
$6.9M
Q1 24
$2.6M
Total Debt
VENU
VENU
VVOS
VVOS
Q4 25
$58.9M
$2.9M
Q3 25
$58.9M
Q2 25
$44.8M
Q1 25
$54.7M
Q4 24
$1.2M
Q3 24
$22.8M
$1.2M
Q2 24
$1.2M
Q1 24
Stockholders' Equity
VENU
VENU
VVOS
VVOS
Q4 25
$122.7M
$-1.5M
Q3 25
$121.2M
$2.5M
Q2 25
$90.2M
$4.6M
Q1 25
$78.4M
$4.4M
Q4 24
$8.0M
Q3 24
$79.4M
$7.7M
Q2 24
$6.3M
Q1 24
$582.0K
Total Assets
VENU
VENU
VVOS
VVOS
Q4 25
$370.6M
$25.2M
Q3 25
$314.8M
$25.6M
Q2 25
$242.0M
$26.0M
Q1 25
$212.9M
$11.3M
Q4 24
$15.3M
Q3 24
$166.6M
$15.3M
Q2 24
$15.8M
Q1 24
$11.8M
Debt / Equity
VENU
VENU
VVOS
VVOS
Q4 25
0.48×
Q3 25
0.49×
Q2 25
0.50×
Q1 25
0.70×
Q4 24
0.15×
Q3 24
0.29×
0.16×
Q2 24
0.19×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
VENU
VENU
VVOS
VVOS
Operating Cash FlowLast quarter
$12.8M
$-3.8M
Free Cash FlowOCF − Capex
$-52.4M
$-5.3M
FCF MarginFCF / Revenue
-1157.6%
-139.7%
Capex IntensityCapex / Revenue
1441.2%
40.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-134.0M
$-17.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
VENU
VENU
VVOS
VVOS
Q4 25
$12.8M
$-3.8M
Q3 25
$6.3M
$-4.2M
Q2 25
$-2.4M
$-3.5M
Q1 25
$-9.0M
$-3.8M
Q4 24
$-2.9M
Q3 24
$-4.2M
Q2 24
$-3.0M
Q1 24
$-2.5M
Free Cash Flow
VENU
VENU
VVOS
VVOS
Q4 25
$-52.4M
$-5.3M
Q3 25
$-32.9M
$-4.2M
Q2 25
$-17.6M
$-4.3M
Q1 25
$-31.1M
$-3.9M
Q4 24
$-3.1M
Q3 24
$-4.4M
Q2 24
$-3.1M
Q1 24
$-2.7M
FCF Margin
VENU
VENU
VVOS
VVOS
Q4 25
-1157.6%
-139.7%
Q3 25
-611.3%
-62.6%
Q2 25
-392.4%
-111.6%
Q1 25
-888.4%
-129.9%
Q4 24
-84.0%
Q3 24
-113.4%
Q2 24
-76.7%
Q1 24
-78.0%
Capex Intensity
VENU
VENU
VVOS
VVOS
Q4 25
1441.2%
40.0%
Q3 25
728.3%
1.2%
Q2 25
337.9%
20.2%
Q1 25
630.1%
4.0%
Q4 24
4.5%
Q3 24
5.0%
Q2 24
1.5%
Q1 24
4.4%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

VENU
VENU

Food And Beverage$2.9M64%
Other$1.6M36%

VVOS
VVOS

Services$3.2M84%
Products$594.0K16%

Related Comparisons